REVELATION BIOSCIENCES INC (REVB) Stock Price, Forecast & Analysis
NASDAQ:REVB • US76135L8046
REVB Key Statistics, Chart & Performance
The current stock price of REVB is 1.3743 USD. In the past month the price decreased by -38.65%. In the past year, price decreased by -96.78%.
REVB Technical Analysis
REVB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to REVB. No worries on liquidiy or solvency for REVB as it has an excellent financial health rating, but there are worries on the profitability.
REVB Financial Highlights
Over the last trailing twelve months REVB reported a non-GAAP Earnings per Share(EPS) of -56.39. The EPS increased by 92.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.52% | ||
| ROE | -127.98% | ||
| Debt/Equity | 0 |
REVB Forecast & Estimates
7 analysts have analysed REVB and the average price target is 86.7 USD. This implies a price increase of 6208.67% is expected in the next year compared to the current price of 1.3743.
REVB Ownership
REVB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.86 | 403.74B | ||
| AMGN | AMGEN INC | 17 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.57 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.86 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.66 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.94 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.77 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.45 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About REVB
Company Profile
Revelation Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
Company Info
REVELATION BIOSCIENCES INC
4660 Lajolla Village Drive, Suite 100
San Diego CALIFORNIA US
Employees: 8
Phone: 13026457400
REVELATION BIOSCIENCES INC / REVB FAQ
Can you describe the business of REVELATION BIOSCIENCES INC?
Revelation Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
What is the current price of REVB stock?
The current stock price of REVB is 1.3743 USD. The price increased by 1.8% in the last trading session.
Does REVB stock pay dividends?
REVB does not pay a dividend.
What is the ChartMill technical and fundamental rating of REVB stock?
REVB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of REVB stock?
REVELATION BIOSCIENCES INC (REVB) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of REVELATION BIOSCIENCES INC (REVB)?
REVELATION BIOSCIENCES INC (REVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-56.39).
Should I buy REVB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on REVB.